Supplementary protection
LT - Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
EN - QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF
SPC
| (11) |
Number of the document |
C 1345910 |
| (68) |
Number of the document |
1345910
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2014 005 |
| (22) |
Date of filing the application |
2014-02-06 |
| (41) |
Date of publication of the application |
2014-03-25 |
|
Date of publication of SPC |
2014-09-25 |
| (24) |
Date of coming into effect of SPC |
2021-12-13 |
Applicant
| (71) |
Boehringer Ingelheim Pharma GmbH & Co.KG,
Binger Strasse 173, 55218 Ingelheim am Rhein,
DE
|
Grantee
| (73) |
Boehringer Ingelheim Pharma GmbH & Co.KG,
Binger Strasse 173, 55218 Ingelheim am Rhein,
DE
|
Attorney or representative
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/13/879/001-EU/1/13/879/012, 2013-09-25
|
Calculated date of expiry of the SPC
| (94) |
2026-12-13 |
Name of the product protected by the basic patent
| (95) |
Afatinibum |
Paediatric extension
|
Request filed |
SPC extension granted until |
Request refused |
|
2022-05-09 |
2027-06-13 |
|
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2024-11-22 |
4 |
347.00
EUR
|
Next renewal fee
|
2025-12-13 |
Legal status
|
SPC term extension granted
|
|
